Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas

Fadzai Chinyengetere, David J. Sekula, Yun Lu, Andrew J. Giustini, Aarti Sanglikar, Masanori Kawakami, Tian Ma, Sandra S. Burkett, Burton L. Eisenberg, Wendy A. Wells, Paul J. Hoopes, Elizabeth G. Demicco, Alexander J. Lazar, Keila E. Torres, Vincent Memoli, Sarah J. Freemantle, Ethan Dmitrovsky

Research output: Contribution to journalArticle

Abstract

Background: USP18 (ubiquitin-specific protease 18) removes ubiquitin-like modifier interferon stimulated gene 15 (ISG15) from conjugated proteins. USP18 null mice in a FVB/N background develop tumors as early as 2 months of age. These tumors are leiomyosarcomas and thus represent a new murine model for this disease. Methods: Heterozygous USP18 +/- FVB/N mice were bred to generate wild-type, heterozygous and homozygous cohorts. Tumors were characterized immunohistochemically and two cell lines were derived from independent tumors. Cell lines were karyotyped and their responses to restoration of USP18 activity assessed. Drug testing and tumorigenic assays were also performed. USP18 immunohistochemical staining in a large series of human leiomyosacomas was examined. Results: USP18 -/- FVB/N mice spontaneously develop tumors predominantly on the back of the neck with most tumors evident between 6-12 months (80 % penetrance). Immunohistochemical characterization of the tumors confirmed they were leiomyosarcomas, which originate from smooth muscle. Restoration of USP18 activity in sarcoma-derived cell lines did not reduce anchorage dependent or independent growth or xenograft tumor formation demonstrating that these cells no longer require USP18 suppression for tumorigenesis. Karyotyping revealed that both tumor-derived cell lines were aneuploid with extra copies of chromosomes 3 and 15. Chromosome 15 contains the Myc locus and MYC is also amplified in human leiomyosarcomas. MYC protein levels were elevated in both murine leiomyosarcoma cell lines. Stabilized P53 protein was detected in a subset of these murine tumors, another feature of human leiomyosarcomas. Immunohistochemical analyses of USP18 in human leiomyosarcomas revealed a range of staining intensities with the highest USP18 expression in normal vascular smooth muscle. USP18 tissue array analysis of primary leiomyosarcomas from 89 patients with a clinical database revealed cases with reduced USP18 levels had a significantly decreased time to metastasis (P=0.0441). Conclusions: USP18 null mice develop leiomyosarcoma recapitulating key features of clinical leiomyosarcomas and patients with reduced-USP18 tumor levels have an unfavorable outcome. USP18 null mice and the derived cell lines represent clinically-relevant models of leiomyosarcoma and can provide insights into both leiomyosarcoma biology and therapy.

Original languageEnglish (US)
Article number886
JournalBMC Cancer
Volume15
Issue number1
DOIs
StatePublished - Nov 10 2015
Externally publishedYes

Fingerprint

Ubiquitin-Specific Proteases
Leiomyosarcoma
Neoplasms
Cell Line
Chromosomes, Human, Pair 15
Deubiquitinating Enzymes
Tissue Array Analysis
Staining and Labeling
Karyotyping
Proteins
Chromosomes, Human, Pair 3
Penetrance

Keywords

  • ISG15
  • Leiomyosarcoma
  • Murine cancer model
  • USP18

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Chinyengetere, F., Sekula, D. J., Lu, Y., Giustini, A. J., Sanglikar, A., Kawakami, M., ... Dmitrovsky, E. (2015). Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas. BMC Cancer, 15(1), [886]. https://doi.org/10.1186/s12885-015-1883-8

Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas. / Chinyengetere, Fadzai; Sekula, David J.; Lu, Yun; Giustini, Andrew J.; Sanglikar, Aarti; Kawakami, Masanori; Ma, Tian; Burkett, Sandra S.; Eisenberg, Burton L.; Wells, Wendy A.; Hoopes, Paul J.; Demicco, Elizabeth G.; Lazar, Alexander J.; Torres, Keila E.; Memoli, Vincent; Freemantle, Sarah J.; Dmitrovsky, Ethan.

In: BMC Cancer, Vol. 15, No. 1, 886, 10.11.2015.

Research output: Contribution to journalArticle

Chinyengetere, F, Sekula, DJ, Lu, Y, Giustini, AJ, Sanglikar, A, Kawakami, M, Ma, T, Burkett, SS, Eisenberg, BL, Wells, WA, Hoopes, PJ, Demicco, EG, Lazar, AJ, Torres, KE, Memoli, V, Freemantle, SJ & Dmitrovsky, E 2015, 'Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas', BMC Cancer, vol. 15, no. 1, 886. https://doi.org/10.1186/s12885-015-1883-8
Chinyengetere F, Sekula DJ, Lu Y, Giustini AJ, Sanglikar A, Kawakami M et al. Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas. BMC Cancer. 2015 Nov 10;15(1). 886. https://doi.org/10.1186/s12885-015-1883-8
Chinyengetere, Fadzai ; Sekula, David J. ; Lu, Yun ; Giustini, Andrew J. ; Sanglikar, Aarti ; Kawakami, Masanori ; Ma, Tian ; Burkett, Sandra S. ; Eisenberg, Burton L. ; Wells, Wendy A. ; Hoopes, Paul J. ; Demicco, Elizabeth G. ; Lazar, Alexander J. ; Torres, Keila E. ; Memoli, Vincent ; Freemantle, Sarah J. ; Dmitrovsky, Ethan. / Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas. In: BMC Cancer. 2015 ; Vol. 15, No. 1.
@article{005070ab54374e448c1588f68849f1da,
title = "Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas",
abstract = "Background: USP18 (ubiquitin-specific protease 18) removes ubiquitin-like modifier interferon stimulated gene 15 (ISG15) from conjugated proteins. USP18 null mice in a FVB/N background develop tumors as early as 2 months of age. These tumors are leiomyosarcomas and thus represent a new murine model for this disease. Methods: Heterozygous USP18 +/- FVB/N mice were bred to generate wild-type, heterozygous and homozygous cohorts. Tumors were characterized immunohistochemically and two cell lines were derived from independent tumors. Cell lines were karyotyped and their responses to restoration of USP18 activity assessed. Drug testing and tumorigenic assays were also performed. USP18 immunohistochemical staining in a large series of human leiomyosacomas was examined. Results: USP18 -/- FVB/N mice spontaneously develop tumors predominantly on the back of the neck with most tumors evident between 6-12 months (80 {\%} penetrance). Immunohistochemical characterization of the tumors confirmed they were leiomyosarcomas, which originate from smooth muscle. Restoration of USP18 activity in sarcoma-derived cell lines did not reduce anchorage dependent or independent growth or xenograft tumor formation demonstrating that these cells no longer require USP18 suppression for tumorigenesis. Karyotyping revealed that both tumor-derived cell lines were aneuploid with extra copies of chromosomes 3 and 15. Chromosome 15 contains the Myc locus and MYC is also amplified in human leiomyosarcomas. MYC protein levels were elevated in both murine leiomyosarcoma cell lines. Stabilized P53 protein was detected in a subset of these murine tumors, another feature of human leiomyosarcomas. Immunohistochemical analyses of USP18 in human leiomyosarcomas revealed a range of staining intensities with the highest USP18 expression in normal vascular smooth muscle. USP18 tissue array analysis of primary leiomyosarcomas from 89 patients with a clinical database revealed cases with reduced USP18 levels had a significantly decreased time to metastasis (P=0.0441). Conclusions: USP18 null mice develop leiomyosarcoma recapitulating key features of clinical leiomyosarcomas and patients with reduced-USP18 tumor levels have an unfavorable outcome. USP18 null mice and the derived cell lines represent clinically-relevant models of leiomyosarcoma and can provide insights into both leiomyosarcoma biology and therapy.",
keywords = "ISG15, Leiomyosarcoma, Murine cancer model, USP18",
author = "Fadzai Chinyengetere and Sekula, {David J.} and Yun Lu and Giustini, {Andrew J.} and Aarti Sanglikar and Masanori Kawakami and Tian Ma and Burkett, {Sandra S.} and Eisenberg, {Burton L.} and Wells, {Wendy A.} and Hoopes, {Paul J.} and Demicco, {Elizabeth G.} and Lazar, {Alexander J.} and Torres, {Keila E.} and Vincent Memoli and Freemantle, {Sarah J.} and Ethan Dmitrovsky",
year = "2015",
month = "11",
day = "10",
doi = "10.1186/s12885-015-1883-8",
language = "English (US)",
volume = "15",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas

AU - Chinyengetere, Fadzai

AU - Sekula, David J.

AU - Lu, Yun

AU - Giustini, Andrew J.

AU - Sanglikar, Aarti

AU - Kawakami, Masanori

AU - Ma, Tian

AU - Burkett, Sandra S.

AU - Eisenberg, Burton L.

AU - Wells, Wendy A.

AU - Hoopes, Paul J.

AU - Demicco, Elizabeth G.

AU - Lazar, Alexander J.

AU - Torres, Keila E.

AU - Memoli, Vincent

AU - Freemantle, Sarah J.

AU - Dmitrovsky, Ethan

PY - 2015/11/10

Y1 - 2015/11/10

N2 - Background: USP18 (ubiquitin-specific protease 18) removes ubiquitin-like modifier interferon stimulated gene 15 (ISG15) from conjugated proteins. USP18 null mice in a FVB/N background develop tumors as early as 2 months of age. These tumors are leiomyosarcomas and thus represent a new murine model for this disease. Methods: Heterozygous USP18 +/- FVB/N mice were bred to generate wild-type, heterozygous and homozygous cohorts. Tumors were characterized immunohistochemically and two cell lines were derived from independent tumors. Cell lines were karyotyped and their responses to restoration of USP18 activity assessed. Drug testing and tumorigenic assays were also performed. USP18 immunohistochemical staining in a large series of human leiomyosacomas was examined. Results: USP18 -/- FVB/N mice spontaneously develop tumors predominantly on the back of the neck with most tumors evident between 6-12 months (80 % penetrance). Immunohistochemical characterization of the tumors confirmed they were leiomyosarcomas, which originate from smooth muscle. Restoration of USP18 activity in sarcoma-derived cell lines did not reduce anchorage dependent or independent growth or xenograft tumor formation demonstrating that these cells no longer require USP18 suppression for tumorigenesis. Karyotyping revealed that both tumor-derived cell lines were aneuploid with extra copies of chromosomes 3 and 15. Chromosome 15 contains the Myc locus and MYC is also amplified in human leiomyosarcomas. MYC protein levels were elevated in both murine leiomyosarcoma cell lines. Stabilized P53 protein was detected in a subset of these murine tumors, another feature of human leiomyosarcomas. Immunohistochemical analyses of USP18 in human leiomyosarcomas revealed a range of staining intensities with the highest USP18 expression in normal vascular smooth muscle. USP18 tissue array analysis of primary leiomyosarcomas from 89 patients with a clinical database revealed cases with reduced USP18 levels had a significantly decreased time to metastasis (P=0.0441). Conclusions: USP18 null mice develop leiomyosarcoma recapitulating key features of clinical leiomyosarcomas and patients with reduced-USP18 tumor levels have an unfavorable outcome. USP18 null mice and the derived cell lines represent clinically-relevant models of leiomyosarcoma and can provide insights into both leiomyosarcoma biology and therapy.

AB - Background: USP18 (ubiquitin-specific protease 18) removes ubiquitin-like modifier interferon stimulated gene 15 (ISG15) from conjugated proteins. USP18 null mice in a FVB/N background develop tumors as early as 2 months of age. These tumors are leiomyosarcomas and thus represent a new murine model for this disease. Methods: Heterozygous USP18 +/- FVB/N mice were bred to generate wild-type, heterozygous and homozygous cohorts. Tumors were characterized immunohistochemically and two cell lines were derived from independent tumors. Cell lines were karyotyped and their responses to restoration of USP18 activity assessed. Drug testing and tumorigenic assays were also performed. USP18 immunohistochemical staining in a large series of human leiomyosacomas was examined. Results: USP18 -/- FVB/N mice spontaneously develop tumors predominantly on the back of the neck with most tumors evident between 6-12 months (80 % penetrance). Immunohistochemical characterization of the tumors confirmed they were leiomyosarcomas, which originate from smooth muscle. Restoration of USP18 activity in sarcoma-derived cell lines did not reduce anchorage dependent or independent growth or xenograft tumor formation demonstrating that these cells no longer require USP18 suppression for tumorigenesis. Karyotyping revealed that both tumor-derived cell lines were aneuploid with extra copies of chromosomes 3 and 15. Chromosome 15 contains the Myc locus and MYC is also amplified in human leiomyosarcomas. MYC protein levels were elevated in both murine leiomyosarcoma cell lines. Stabilized P53 protein was detected in a subset of these murine tumors, another feature of human leiomyosarcomas. Immunohistochemical analyses of USP18 in human leiomyosarcomas revealed a range of staining intensities with the highest USP18 expression in normal vascular smooth muscle. USP18 tissue array analysis of primary leiomyosarcomas from 89 patients with a clinical database revealed cases with reduced USP18 levels had a significantly decreased time to metastasis (P=0.0441). Conclusions: USP18 null mice develop leiomyosarcoma recapitulating key features of clinical leiomyosarcomas and patients with reduced-USP18 tumor levels have an unfavorable outcome. USP18 null mice and the derived cell lines represent clinically-relevant models of leiomyosarcoma and can provide insights into both leiomyosarcoma biology and therapy.

KW - ISG15

KW - Leiomyosarcoma

KW - Murine cancer model

KW - USP18

UR - http://www.scopus.com/inward/record.url?scp=84946744829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946744829&partnerID=8YFLogxK

U2 - 10.1186/s12885-015-1883-8

DO - 10.1186/s12885-015-1883-8

M3 - Article

C2 - 26555296

AN - SCOPUS:84946744829

VL - 15

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 886

ER -